Economic evaluation of Chagas disease screening of pregnant Latin American women and of their infants in a non endemic area

Acta Tropica

Volumn 118, Issue 2, 2011, Pages 110-117

  Sicuri, Elisa ^a   Muñoz, José ^a   Pinazo, Maria Jesús ^a   Posada, Elizabeth ^a   Sanchez, Joan ^a   Alonso, Pedro L ^a,b   Gascon, Joaquim ^a  

^a CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^b Ministério de Saúde   (Mozambique)

Author keywords

Chagas disease; Decision model; Monte Carlo simulation; Vertical transmission

Indexed keywords

CHAGAS DISEASE; DISEASE PREVALENCE; ECONOMIC IMPACT; LATINO PEOPLE; PREGNANCY; VERTICAL TRANSMISSION;

ARTICLE; CHAGAS DISEASE; CONGENITAL INFECTION; COST EFFECTIVENESS ANALYSIS; DECISION TREE; EARLY DIAGNOSIS; FEMALE; HISPANIC; HUMAN; INFANT; MONTE CARLO METHOD; NEWBORN; NEWBORN SCREENING; PREGNANT WOMAN; PRENATAL SCREENING; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SEROLOGY; SPAIN; VERTICAL TRANSMISSION;

CHAGAS DISEASE; COST-BENEFIT ANALYSIS; EMIGRANTS AND IMMIGRANTS; FEMALE; HUMANS; INFANT, NEWBORN; MASS SCREENING; PARASITOLOGY; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SPAIN;

SPAIN;

EID: 79955466712     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.actatropica.2011.02.012     Document Type: Article

References (41)

1. Adam T., Koopmanschap M.A., Evans D.B. Cost-effectiveness analysis: can we reduce variability in costing methods?. Int. J. Technol. Assess. Health Care 2003, 19:407-420.
2. Ades A.E., Sculpher M.J., Gibb D.M., Gupta R., Ratcliffe J. Cost effectiveness analysis of antenatal HIV screening in United Kingdom. BMJ 1999, 319:1230-1234.
3. Akhavan D. Analise de Custo-Efectivadade do Programa de Controle da Doença de Chagas no Brasil 1996, National Health Foundation, Brasilia.
4. Basombrio M.A., Schofield C.J., Rojas C.L., del Rey E.C. A cost-benefit analysis of Chagas disease control in north-western Argentina. Trans. R. Soc. Trop. Med. Hyg. 1998, 92:137-143.
5. Bern C., Montgomery S.P. An estimate of the burden of Chagas disease in the United States. Clin. Infect. Dis. 2009, 49:e52-e54.
6. Billot C., Torrico F., Carlier Y. Cost effectiveness study of a control program of congenital Chagas disease in Bolivia. Rev. Soc. Bras. Med. Trop. 2005, 38(Suppl. 2):108-113.
7. Blanco S.B., Segura E.L., Cura E.N., Chuit R., Tulian L., Flores I., Garbarino G., Villalonga J.F., Gurtler R.E. Congenital transmission of Trypanosoma cruzi: an operational outline for detecting and treating infected infants in north-western Argentina. Trop. Med. Int. Health 2000, 5:293-301.
8. Briggs A.H. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000, 17:479-500.
9. Briggs A.H., Goeree R., Blackhouse G., O'Brien B.J. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med. Decis. Making 2002, 22:290-308.
10. Briggs A.H., Mooney C.Z., Wonderling D.E. Constructing confidence intervals for cost-effectiveness ratios: an evaluation of parametric and non-parametric techniques using Monte Carlo simulation. Stat. Med. 1999, 18:3245-3262.
11. Castillo-Riquelme M., Guhl F., Turriago B., Pinto N., Rosas F., Martinez M.F., Fox-Rushby J., Davies C., Campbell-Lendrum D. The costs of preventing and treating Chagas disease in Colombia. PLoS Negl. Trop. Dis. 2008, 2:e336.
12. Claxton K., Sculpher M., Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence (NICE). Lancet 2002, 360:711-715.
13. Cohen D.J., Breall J.A., Ho K.K., Weintraub R.M., Kuntz R.E., Weinstein M.C., Baim D.S. Economics of elective coronary revascularization. Comparison of costs and charges for conventional angioplasty, directional atherectomy, stenting and bypass surgery. J. Am. Coll. Cardiol. 1993, 22:1052-1059.
14. Di Pentima M.C., Hwang L.Y., Skeeter C.M., Edwards M.S. Prevalence of antibody to Trypanosoma cruzi in pregnant Hispanic women in Houston. Clin. Infect. Dis. 1999, 28:1281-1285.
15. Drummond M., Weatherly H., Ferguson B. Economic evaluation of health interventions. BMJ 2008, 337:a1204.
16. Flores-Chávez M., Cruz I., Rodríguez M., Nieto J., Franco E., Gárate T., Cañavate C. Comparison of conventional and non-conventional serological tests for the diagnosis of imported Chagas disease in Spain. Enferm. Infecc. Microbiol. Clin. 2010, 28:284-293.
17. Frank M., Hegenscheid B., Janitschke K., Weinke T. Prevalence and epidemiological significance of Trypanosoma cruzi infection among Latin American immigrants in Berlin, Germany. Infection 1997, 25:355-358.
18. Gascon J., Pinazo M.J. Controlling vertical transmission of Trypanosoma cruzi: the biggest challenge for imported disease in Spain. Enferm. Infecc. Microbiol. Clin. 2008, 26:607-608.
19. Gold M. Panel on cost-effectiveness in health and medicine. Med. Care 1996, 34:DS197-DS199.
20. Instituto Nacional Estadistica, Instituto Nacional Estadistica (INE). (accessed 16.12.10). http://www.ine.es/.
21. Miyoshi C., Tanabe M., Kawai S., Honda S., Sakuma F., Katayama T., Rojas E., Rosado D. Chagas' disease among blood donors in Bolivia. Nippon Koshu Eisei Zasshi 1994, 41:1027-1031.
22. Munoz J., Coll O., Juncosa T., Verges M., del Pino M., Fumado V., Bosch J., Posada E.J., Hernandez S., Fisa R., Boguna J.M., Gallego M., Sanz S., Portus M., Gascon J. Prevalence and vertical transmission of Trypanosoma cruzi infection among pregnant Latin American women attending 2 maternity clinics in Barcelona, Spain. Clin. Infect. Dis. 2009, 48:1736-1740.
23. Munoz J., Portus M., Corachan M., Fumado V., Gascon J. Congenital Trypanosoma cruzi infection in a non-endemic area. Trans. R. Soc. Trop. Med. Hyg. 2007, 101:1161-1162.
24. Murray C.J.L., Lopez A.D. The Global Burden of Disease 1996, Harvard School of Public Health.
25. Nigrovic L.E., Chiang V.W. Cost analysis of enteroviral polymerase chain reaction in infants with fever and cerebrospinal fluid pleocytosis. Arch. Pediatr. Adolesc. Med. 2000, 154:817-821.
26. Oliveira I., Torrico F., Munoz J., Gascon J. Congenital transmission of Chagas disease: a clinical approach. Expert Rev. Anti Infect. Ther. 2010, 8:945-956.
27. Pellegrino A. Migration from Latin America to Europe: Trends and Policy Challenges 2004, Migration Research Series No. 16.
28. Pinto Dias J.C. Epidemiologia. Trypanosoma cruzi e doença da Chagas 2000, 48-74. Rio de Janeiro. Brener, Andrade, Barral-Netto (Eds.).
29. Piron M., Verges M., Munoz J., Casamitjana N., Sanz S., Maymo R.M., Hernandez J.M., Puig L., Portus M., Gascon J., Sauleda S. Seroprevalence of Trypanosoma cruzi infection in at-risk blood donors in Catalonia (Spain). Transfusion 2008, 48:1862-1868.
30. Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect. Dis. 2001, 1:92-100.
31. Rassi A., Rassi A., Marin-Neto J.A. Chagas disease. Lancet 2010, 375:1388-1402.
32. Schmunis G.A. Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem. Inst. Oswaldo Cruz 2007, 102(Suppl. 1):75-85.
33. Sosa Estani S., Segura E.L., Ruiz A.M., Velazquez E., Porcel B.M., Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am. J. Trop. Med. Hyg. 1998, 59:526-529.
34. Suarez E., Alonso-Vega C., Torrico F., Cordova M. Integral treatment of congenital Chagas disease: the Bolivian experience. Rev. Soc. Bras. Med. Trop. 2005, 38(Suppl. 2):21-23.
35. Tibayrenc M., Telleria J. American Trypanosomiasis: Chagas Disease One Hundred Years of Research 2010, Elsevier.
36. Vazquez-Prokopec G.M., Spillmann C., Zaidenberg M., Kitron U., Gurtler R.E. Cost-effectiveness of Chagas disease vector control strategies in Northwestern Argentina. PLoS Negl. Trop. Dis. 2009, 3:e363.
37. Viotti R., Vigliano C., Lococo B., Alvarez M.G., Petti M., Bertocchi G., Armenti A. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev. Anti Infect. Ther. 2009, 7:157-163.
38. Viotti R., Vigliano C., Lococo B., Bertocchi G., Petti M., Alvarez M.G., Postan M., Armenti A. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann. Intern. Med. 2006, 144:724-734.
39. WHO, 2002. Control of Chagas' disease. Second Report of the WHO Expert Committee, WHO Techical Report Series 905, World Health Organization, Geneva.
40. Wilson L.S., Strosberg A.M., Barrio K. Cost-effectiveness of Chagas disease interventions in Latin America and the Caribbean: Markov models. Am. J. Trop. Med. Hyg. 2005, 73:901-910.
41. Zupancic J.A., Richardson D.K., O'Brien B.J., Eichenwald E.C., Weinstein M.C. Cost-effectiveness analysis of predischarge monitoring for apnea of prematurity. Pediatrics 2003, 111:146-152.